No improvement in clinical outcomes occurred among inpatients with COVID-19 who received nirtmatrelvir-ritonavir or molnupiravir in addition to usual care.

Aluminum-adsorbed vaccines do not increase risk for autoimmune disorder, atopic or allergic disorder, or neurodevelopmental disorder.

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.